First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study()

AIM: The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. METHODS: Eligible pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Volkmar, Ruhnke, Markus, Hoffmann, Oliver, Grafe, Andrea, Tomé, Oliver, Fett, Werner, Bruch, Harald-Robert, Sommer-Joos, Ann-Katrin, Schneeweiss, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424587/
https://www.ncbi.nlm.nih.gov/pubmed/34488065
http://dx.doi.org/10.1016/j.breast.2021.08.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424587/
https://www.ncbi.nlm.nih.gov/pubmed/34488065
http://dx.doi.org/10.1016/j.breast.2021.08.014

Ejemplares similares